This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Two major disadvantages of cisplatin therapy of cancer are the development of drug resistance in the tumor, nephrotoxicity and neurotoxicity. The prodrug amifostine (WR-2721, Ethyol), S-2 [3-aminopropylamino] ethylphosphorothioic acid has been used to protect normal tissues against adverse effects of cancer therapy with cisplatin. However, whether amifostine compromises cancer treatment efficacy by protecting the tumor is not clearly resolved. In clinical studies of amifostine administration along with cisplatin have not been sufficiently long to detect any treatment failures (i.e., tumor recurrence) that can be attributed to the use of amifostine in combination with cisplatin. This is intriguing because the prodrug amifostine is dephosphorylated by alkaline phosphatases (present in normal tissues and vasculature and certain tumors including lung cancer) to the active amino thiol form of the drug, WR-1065. Thiols can chemically inactivate cisplatin and other drugs. The lack of amifostine mediated inactivation of cisplatin and other drugs during cancer treatment may be due to inadequate distribution of amifostine and its metabolite (relative to cisplatin) in poorly vascularized tumors, which may be deficient in alkaline phosphatase. This bears further scrutiny in view of the numerous reports associating alkaline phosphatase with a variety of tumors. Tumors differ with respect to thiol content, alkaline phosphatase activity, and vascular density. Therefore tumors will differ in their ability to activate the prodrug amifostine. Several tumor cell lines were surveyed and found to differ considerably with respect to their alkaline phosphatase activity and consequently their ability to activate the prodrug amifostine to its active thiol form. Inhibitors of alkaline phosphatase altered the kinetics of dephosphorylation of amifostine. This underscores the importance of identifying tumors with high alakaline phosphatase levels, since amifostine will be protect against cisplatin. Noninvasive techniques for monitoring dephosphorylation of amifostine in tumors will permit individualization of treatment strategies. We have found that a nitric oxide (NO) donor such as nitroaspirin is cytotoxic to cisplatinum resistant cancer cells which contain high levels of thiols. Such NO donors may be useful in cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003048-20
Application #
7561456
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-06-01
Project End
2008-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
20
Fiscal Year
2007
Total Cost
$99,464
Indirect Cost
Name
Howard University
Department
Administration
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Khan, Farhan; Ricks-Santi, Luisel J; Zafar, Rabia et al. (2018) Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women. Ann Diagn Pathol 34:170-174
Khan, Farhan; Esnakula, Ashwini; Ricks-Santi, Luisel J et al. (2018) Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women. Pathol Res Pract 214:673-678
Dguzeh, Ucee; Haddad, Natasha C; Smith, Kathia T S et al. (2018) Alcoholism: A Multi-Systemic Cellular Insult to Organs. Int J Environ Res Public Health 15:
Ricks-Santi, Luisel; McDonald, J Tyson; Gold, Bert et al. (2017) Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. Ethn Dis 27:169-178
Haddad, Georges E (2017) Modified mRNAs in the Cardiovascular System: A New Platform for Gene Therapy. Mol Ther 25:1266-1268
Faruque, Mezbah U; Chen, Guanjie; Doumatey, Ayo P et al. (2017) Transferability of genome-wide associated loci for asthma in African Americans. J Asthma 54:1-8
Nakhoul, Marie R; Seif, Karl E; Haddad, Natasha et al. (2017) Fetal Alcohol Exposure: The Common Toll. J Alcohol Drug Depend 5:
Zhao, Yuan; Ling, Zhiqiang; Hao, Yubin et al. (2017) MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. Oncotarget 8:25005-25020
Johnston, Henry Richard; Hu, Yi-Juan; Gao, Jingjing et al. (2017) Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. Sci Rep 7:46398
Sridhar, Rajagopalan; Bond Jr, Vernon; Dunmore-Griffith, Jacquelyn et al. (2017) Relationship Between Aerobic Fitness, the Serum IGF-1 Profiles of Healthy Young Adult African American Males, and Growth of Prostate Cancer Cells. Am J Mens Health 11:92-98

Showing the most recent 10 out of 239 publications